EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)

被引:507
作者
Madersbacher, S
Alivizatos, G
Nordling, J
Sanz, CR
Emberton, M
de la Rosette, JJMCH
机构
[1] Univ Amsterdam, AMC Univ Hosp, Dept Urol, NL-1100 DE Amsterdam, Netherlands
[2] Donauspital, Dept Urol & Androl, Vienna, Austria
[3] Sismanoglio Hosp, Athens Med Sch, Urol Dept 2, Athens, Greece
[4] Univ Copenhagen, Herlev Hosp, Dept Urol, Copenhagen, Denmark
[5] Univ Zaragoza, Hosp Miguel Servet, Dept Urol, Zaragoza, Spain
[6] UCL Royal Free & Univ Coll Med Sch, Inst Urol, London, England
关键词
BPH; prostate; guidelines; treatment; diagnosis;
D O I
10.1016/j.eururo.2004.07.016
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To provide the first update of the EAU guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO). Methods: A systematic literature review was conducted based on the results of a MEDLINE(R) search concentrating on the years 1999-2003. In combination with expert opinions recommendations were made on the usefulness of diagnostic tests, therapeutic options and follow-up. Results: During initial assessment the following tests are recommended: medical history, physical examination including digital-rectal examination, International Prostate Symptom Score, urinalysis, serum creatinine and prostate specific antigen measurement, uroflowmetry and post-void residual volume. All other tests are optional or not recommended. Aim of treatment is to improve LUTS and quality of life and to prevent severe BPE-related complications. Development of a 5alpha-reductase type I and II inhibitor and the data of the MTOPS trial providing scientific evidence for a combination therapy were the most significant innovations since the first version. Finally a more detailed knowledge on the natural history with identification of several risk factors for progression is the basis for a risk-profile orientated (preventive) therapy. Conclusions: Updated recommendations for assessment, treatment, and follow-up of patients with LUTS due to BPO are presented. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:547 / 554
页数:8
相关论文
共 37 条
[1]   The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk [J].
Anderson, JB ;
Roehrborn, CG ;
Schalken, JA ;
Emberton, M .
EUROPEAN UROLOGY, 2001, 39 (04) :390-398
[3]   Could self-management challenge pharmacotherapy as a longterm treatment for uncomplicated lower urinary tract symptoms? [J].
Brown, CT ;
Emberton, M .
CURRENT OPINION IN UROLOGY, 2004, 14 (01) :7-12
[4]   A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia [J].
Bruskewitz, R ;
Issa, MM ;
Roehrborn, CG ;
Naslund, MJ ;
Perez-Marrero, R ;
Shumaker, BP ;
Oesterling, JE .
JOURNAL OF UROLOGY, 1998, 159 (05) :1588-1593
[5]  
Chapple C R, 2001, Curr Opin Urol, V11, P9, DOI 10.1097/00042307-200101000-00002
[6]   Side-firing neodymium: YAG laser prostatectomy [J].
Costello, AJ ;
Kabalin, JN .
EUROPEAN UROLOGY, 1999, 35 (02) :138-146
[7]   Transurethral microwave thermotherapy: The gold standard for minimally invasive therapies for patients with benign prostatic hyperplasia? [J].
De La Rosette, JJMCH ;
Laguna, MP ;
Gravas, S ;
De Wildt, MJAM .
JOURNAL OF ENDOUROLOGY, 2003, 17 (04) :245-251
[8]   EAU guidelines on benign prostatic hyperplasia (BPH) [J].
de la Rosette, JJMCH ;
Alivizatos, G ;
Madersbacher, S ;
Perachino, M ;
Thomas, D ;
Desgrandchamps, F ;
De Wildt, M .
EUROPEAN UROLOGY, 2001, 40 (03) :256-263
[9]   Clinical results of microwave thermotherapy for benign prostatic hyperplasia [J].
De Wildt, MJAM ;
Wagrell, L ;
Larson, TR ;
Eliasson, T .
JOURNAL OF ENDOUROLOGY, 2000, 14 (08) :651-656
[10]   Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia:: A 1-year randomized international study [J].
Debruyne, F ;
Koch, G ;
Boyle, P ;
Da Silva, FC ;
Gillenwater, JG ;
Hamdy, FC ;
Perrin, P ;
Teillac, P ;
Vela-Navarrete, R ;
Raynaud, JP .
EUROPEAN UROLOGY, 2002, 41 (05) :497-506